Does pharma R&D need a strategic reset? Adapting to a changing US landscape.

Area of Science:

• Biomedical innovation
• Pharmaceutical industry
• Health economics

Background:

• Research-based pharmaceutical companies traditionally rely on the U.S. as a stable hub for innovation, talent, and markets.
• The biotech-leveraged pharma company (BIPCO) model is predicated on U.S. market strengths.
• Recent geopolitical shifts and U.S. policy changes are undermining this established foundation.

Purpose of the Study:

• To analyze the impact of geopolitical shifts on the pharmaceutical R&D business model.
• To identify emerging strategic risks for pharmaceutical R&D.
• To underscore the need for strategic realignment in the pharmaceutical industry.

Main Methods:

• Qualitative analysis of geopolitical trends and policy changes affecting the pharmaceutical sector.
• Assessment of the U.S. as a historical hub for biomedical innovation.
• Review of traditional pharmaceutical R&D business models and their vulnerabilities.

Main Results:

• The U.S. is no longer a secure "safe harbor" for pharmaceutical R&D due to policy changes like FDA budget cuts and tariffs.
• Pharmaceutical R&D is exposed to new strategic risks beyond its previous scope.
• The traditional U.S.-centric innovation model is weakening, impacting R&D productivity.

Conclusions:

• Pharmaceutical companies must urgently rethink R&D pipelines, technology acquisition, and global operational strategies.
• Supply chain and tax strategies require adjustment in response to geopolitical instability.
• The long-term viability of the current pharmaceutical R&D model, reliant on U.S. leadership, is uncertain and necessitates strategic realignment.